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Abstract
Introduction:  Multiple  studies  have  reported  strong  associations  between  Helicobacter  pylori
(Hp) inﬂammation  and  gastric  cancer  (GC)  development.  Altered  expressions  of  pro/anti-
inﬂammatory  cytokines  have  a  crucial  role  in  Hp  and  GC  proliferation.  Although  there  are  many
studies related  to  cytokines  polymorphisms  involvement  in  GC  risk,  the  role  of  Interleukin-4
(IL-4) and  Interleukin-6  (IL-6)  in  gastric  inﬂammation  process  is  not  yet  clariﬁed.
Aim: This  study  aimed  to  investigate  the  impact  of  common  IL-4  and  IL-6  polymorphisms  in  GC
development  risk  among  Portuguese  population.
Methods:  A  total  of  100  GC  biopsies  (50  with  intestinal  type,  IGC,  50  with  diffuse  type,  DGC)
and 50  chronic  gastritis  cases,  used  as  control  group,  were  included  in  this  case-control  study.
IL-4 and  IL-6  common  polymorphisms  were  genotyped  by  PCR-SSP,  using  commercially  available
kits.
Results: IL-4  low  producer  genotypes,  IL-4-590TT  (OR  =  6.7;  95%  CI  1.4--32.4)  and  IL-4-1098GG
(OR =  4.4;  95%  CI  1.7--16.9)  were  found  associated  with  IGC  and  DGC,  respectively.  We  also
veriﬁed  that  IL-4  TTT  haplotype  was  linked  with  both  IGC  (OR  =  5.8;  95%  CI  2.3--14.4)  and
DGC (OR  =  2.3;  95%  CI  1.0--5.5)  groups.  Concerning  IL-6  results,  IL-6-174CG  genotype  showed
a higher  prevalence  among  IGC  cases  (OR  =  7.3;  95%  CI  2.7--20.3),  and  IL-6-174CC  (OR  =  3.8;  95%
CI 1.7--8.7)  showed  upper  prevalence  within  DGC  subjects.  Finally,  IL-6-174/nt565CG  haplotype
showed a  signiﬁcant  association  with  both  IGC  (OR  =  7.3;  95%  CI  2.7--20.3)  and  DGC  (OR  =  7.9;
95% CI  4.2--14.9).∗ Corresponding author.
E-mail address: lcarvalho@huc.min-saude.pt (L. Carvalho).
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Conclusion:  IL-6  and  IL-4  expression  variants  seem  to  have  an  important  role  in  GC  risk  mecha-
nisms. This  study  provides  preliminary  evidence  that  IL-4  and  IL-6  polymorphisms,  although  not
directly linked  to  the  disease,  may  be  useful  tools  in  the  study  of  this  multifactorial  disease.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Associac¸ão  entre  Variantes  de  Expressão  da  IL-4  e  IL-6  e  o  Cancro  Gástrico  na
Populac¸ão  Portuguesa
Resumo
Introduc¸ão:  Múltiplos  estudos  têm  referenciado  fortes  associac¸ões  entre  infec¸ão/inﬂamac¸ão
por Helicobacter  pylori  (Hp)  e  o  desenvolvimento  do  cancro  gástrico  (CG).  A  alterac¸ão  na
expressão  das  citocinas  pro/anti-inﬂamatórias  desempenha  um  papel  crucial  na  proliferac¸ão
da Hp  e  do  CG.  Apesar  de  existirem  vários  estudos  relacionados  com  os  polimorﬁsmos  das
citocinas envolvidos  na  progressão  do  CG,  o  papel  da  Interleukin-4  (IL-4)  e  Interleukin-6  (IL-6)
no mecanismo  de  inﬂamac¸ão  gástrica  ainda  não  está  totalmente  esclarecido.
Objetivo:  Este  estudo  teve  como  objetivo  principal  estudar  o  impacto  dos  polimorﬁsmos  comuns
da IL-4  e  IL-6  no  risco  de  desenvolvimento  do  CG  na  populac¸ão  Portuguesa.
Métodos:  Um  total  de  100  biópsias  de  CG  (50  do  tipo  intestinal,  CGI,  50  do  tipo  difuso,  CGD)
e 50  casos  de  gastrite  crónica,  utilizados  como  grupo  controlo,  foram  incluídos  neste  estudo
de caso-controlo.  Os  polimorﬁsmos  da  IL-4  e  da  IL-6  foram  genotipados  por  PCR-SSP,  utilizando
kits comerciais  disponíveis.
Resultados:  Os  genótipos  de  baixa  produc¸ão  da  IL-4,  IL-4  -590TT  (OR  =  6,7;  95%  CI  1,4  a  32,4)
e IL-4  -1098GG  (OR  =  4,4;  95%  CI  1,7  a  16,9)  encontram-se  associados  com  o  CGI  e  com  o  CGD,
respetivamente.  Também  veriﬁcámos  que  o  haplótipo  IL-4  TTT  encontra-se  relacionado  com
ambos os  grupos  de  CGI  (OR  =  5,8;  95%  CI  2,3  a  14,4)  e  CGD  (OR  =  2.3;  95%  CI  1,0  a  5,5).  Con-
siderando os  resultados  da  IL-6,  o  genótipo  IL-6-174CG  apresentou  uma  elevada  prevalência
entre os  pacientes  com  CGI  (OR  =  7,3;  95%  CI  2,7  a  20,3),  e  o  IL-6  -174CC  (OR  =  3,8;  95%  CI  1,7  a
8,7) apresentou  maior  prevalência  no  grupo  de  CGD.  Finalmente,  o  haplótipo  IL-6  -174/nt565CG
apresentou  uma  associac¸ão  signiﬁcativa  com  ambos  os  grupos  de  CGI  (OR  =  7,3;  95%  CI  2,7  a  20,3)
e CGD  (OR  =  7,9;  95%  CI  4,2  a  14,9).
Conclusão:  Os  variantes  de  expressão  da  IL-6  e  IL-4  parecem  desempenhar  um  papel  importante
nos mecanismos  de  progressão  do  CG.  Este  estudo  fornece  evidências  preliminares  de  que  os
polimorﬁsmos  da  IL-4  e  da  IL-6,  apesar  de  não  estarem  diretamente  ligados  a  esta  patologia,
podem ser  ferramentas  úteis  no  estudo  desta  doenc¸a  multifatorial.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Este  é
um artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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s. Introduction
astric  cancer  (GC)  is  one  of  the  most  important  pub-
ic  health  problem,  with  high  mortality  and  poor  survival
rognosis  worldwide.1--4 Like  other  types  of  cancers,  GC
s  multifactorial  resulting  from  many  environmental  and
enetic  factors  interplay.3,5 Among  those  environmental
actors,  Helicobacter  pylori  (Hp)  infection  is  identiﬁed
s  one  of  the  major  causes  of  GC  development.6,7
t  is  well  known  that  Hp  infection  causes  extensive
nﬂammation  in  gastric  mucosa  that  could  result  in
trophic  gastritis,  intestinal  metaplasia,  dysplasia  and
8,9ancer.
Several  works  also  reported  that  cytokine  levels  are
eregulated  in  Hp-infected  gastric  tissue  and  are  associ-
ted  with  precancerous  lesions  development.5,9 Cytokine
a
a
I
ixpression  levels  could  be  inﬂuenced  by  polymorphic  vari-
nts  in  speciﬁc  gene  regions  that  could  differ  among
ifferent  individuals.10--14 Such  knowledge  indicate  that
mmune  responsiveness  to  cancer,  and  particularly  to
C,  can  be  inﬂuenced  by  speciﬁc  pro/anti-inﬂammatory
ytokine  genotypes.8--14
Although  there  are  several  studies  related  to  cytokines
olymorphisms  involvement  in  Hp  infection  and  GC
rogression,15,16 namely  IL-4  and  IL-6,17,18 its  role  in  gas-
ric  inﬂammation  mechanisms  is  not  yet  clariﬁed.  IL-4  and
L-6  are  involved  in  inﬂammation  processes  been  respon-
ible  for  inﬂammatory  cascade  activation.  Those  cytokines
re  very  important  at  systemic  level,  regulating  ﬁbroblasts
nd  epithelial  cells  and  other  molecules  secretion  (such  as
L1-Ra,  IL-10,  IL-13,  IL-1, IL-8,  etc.. . .).17,18 Recent  stud-
es  indicate  that  IL-6,  and  maybe  IL-4,  are  also  involved  in
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Figure  1  Histology  of  gastric  mucosa.  (A)  Normal  histology  of  gastric  mucosa  (100×,  HE).  (B)  Intestinal  gastric  cancer  (200×,
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THE). (C)  Diffuse  gastric  cancer  (200×,  HE).  Photos  taken  using  a
Bandpass Filter  Sets.
E-Cadherin  carcinogenesis  pathway  among  GC  diffuse  type
patients.19,20
IL-4  is  an  important  immunomodulatory  cytokine,21,22
which  regulates  balance  between  T  helpers  (Th)  1  and  Th2
immune  response.17,18,21,22 There  are  several  polymorphisms
described  in  IL-4  gene,  including  the  -1098  (T  to  G),  -590  (C
to  T)  and  -33  (C  to  T)  mutations,  in  promoter  region.16,21--25
Those  mutations  form  several  haplotypes,  namely:  TCC
(high  producer),  TTT  (intermediate  producer),  GCC  and  GTT
(low  producers).21--24 These  haplotypes  are  associated  with
differences  in  IL-4  expression  and  total  immunoglobulin-E
levels23,24 that  could  affect  the  risk  of  infection,  autoimmu-
nity  and  cancer  development.16,21
IL-6  is  also  a  central  cytokine,  involved  in  multiple  phys-
iological  and  pathophysiological  processes,  implicated  in
pathogenesis  and  cancer  development. 26--32 As  IL-4,  IL-6
gene  has  several  polymorphisms  in  the  promoter  region  that
can  regulate  its  expression.17,26 Among  them,  the  substitu-
tion  of  C  to  G  at  position  -174  and  the  substitution  of  G  for  A
at  nucleotide  565  are  the  most  studied.26--32 These  mutations
form  4 different  haplotypes:  GG,  GA  (high  producers  haplo-
types),  CG  and  CA  (low  producers  haplotypes).28,30,31 IL-6
haplotypes  are  associated  with  differences  in  the  expres-
sion  level  of  IL-6,17,30 that  can  inﬂuence  the  risk  cancer,  and
particularly  GC.26--32
Since  IL-4  and  IL-6  polymorphisms  are  responsible  for  dif-
ferent  cytokine  expression  levels  among  individuals,  that
consequently  control  the  immune  responsiveness  to  Hp-
infection  and  GC,  and  also  because  the  role  of  this  two
cytokines  polymorphisms  in  GC  pathological  and  histologi-
cal  progression  has  not  been  fully  solved,  our  study  aims
to  clarify  these  issues  by  coming  across  the  relationship
between  IL-4  and  Il-6  genotypes  and  GC  types,  as  well  as
their  interaction  with  other  cytokines.
2. Methods
2.1.  Population50  Chronic  Gastritis  (CG)  control  samples  (mean  age  of
57.2  ±  17.4  years;  62%  men  and  38%  women);  50  GC  patients
with  intestinal  type  (mean  age  of  73.3  ±  15.7  years;  62%  men
p
p
(
aescence  microscope  Nikon  (Tokyo,  Japan)  equipped  with  Triple
nd  38%  women)  and  50  from  diffuse  type  (mean  age  of
5  ±  16.4  years;  60%  men  and  40%  women)  biopsies  formalin-
xed  parafﬁn-embedded  (FFPE)  were  selected.  The  cases
ere  randomly  collected  from  2009  to  2011  subjects  from
he  archives  of  Institute  of  Anatomic  Pathology,  Faculty  of
edicine  of  the  University  of  Coimbra.
Gastritis  samples  were  clinically  identiﬁed  as  chronic
sing  the  Sydney  updated  scoring  system  (i.e.,  0  =  none,
 =  slight,  2  =  moderate,  and  3  =  marked)33 and  were  selected
ccording  Hp-infection  positivity,  using  hematoxylin-eosin
taining  technique  (Fig.  1).34
GC  samples  were  clinically  identiﬁed  as  belonging  to  gas-
ric  antrum  carcinomas  and  were  selected  according  to  the
alignant  cells  availability  with  at  least  60  malignant  cells.
he  GC  cases  were  classiﬁed  according  to  Lauren’s  criteria
s:  intestinal  type  (IGC)  and  diffuse  type  (DGC)  (Fig.  1).35
Subjects  with  alcohol  and  smoke  clinical  histories  were
xcluded  from  the  study.  This  study  was  supported  and
pproved  by  local  ethics  committee  (CIMAGO  --  Faculty  of
edicine  of  the  University  of  Coimbra,  Coimbra,  Portugal).
.2.  DNA  extraction
ach  biopsy  was  microdissected  in  order  to  separate  nor-
al  from  affected  tissues  and  genomic  DNA  was  extracted
ccording  QIAamp® DNA  FFPE  Tissue  kit  (QIAGEN,  Califórnia,
UA)  manufacturer  protocol,  using  only  the  normal  portion
f  the  tissue.  The  DNA’s  quality  and  concentration  values
ere  evaluated  using  GeneQuant  Pro  (Biochrom,  Cambridge,
ngland).
.3.  Polymorphisms  genotyping
olymorphisms  genotyping  (Table  1)  were  carried  through
ommercial  kits  ‘‘Cytokine  Box  Kit’’  (Genebox,  Cantanhede
-  Portugal)  using  PCR-SSP  technique,  these  kits  included
nternal,  negative  and  positive  controls  form  each  sample.
he  ampliﬁcation  of  IL-4  and  IL-6  promotor  mutations  was
erformed  using  manufacturer  protocol.  The  ampliﬁed  PCR
roducts  were  analyzed  by  electrophoresis  with  a  SYBR  Safe
Molecular  Probes,  Oregon  --  USA)  2%  agarose  gel  and  visu-
lized  in  a  UV  transilluminator.
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Table  1  IL-4  and  IL-6  polymorphisms  description.
Cytokine  NCBI  SNP
DataBase
Gene  region  Position  Alleles
IL-4
rs2243248  Promotor  -1098  T>G
rs2243250  Promotor  -590  C>T
rs2070874  UTR  -33  C>T
IL-6
rs1800795  Promotor  -174  C>G
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that  could  progresses  for  mucosa  atrophy  (atrophic  gas-rs1800797  Promotor  nt565  G>A
.4.  Genotyping  quality  control
rimers  speciﬁcity  evaluation  was  executed  using  DNA  from
HWG  Cytokine  panel  (from  International  Histocompatibility
orking  Group).  Seven  samples  (14%  of  the  total  samples)
rom  each  group  were  re-analysed  by  Sanger  sequencing
echnique,  using  capillary  electrophoresis  system  (Applied
iosystem,  Lifescience  Technology,  USA),  having  full  geno-
yping  correspondence.
.5.  Statistical  analysis
L-4  (-1098  T>  G;  -590  C>  T;  -33  C>  T)  and  IL-6  (nt565  G>  A;  -
74  C>  G)  frequencies  were  compared  between  groups  (GCD
ersus  CG;  GCI  versus  CG)  using  the  STATISTICA  14  (StatSoft,
nc.,  2013)  based  on  chi-square  (2  ×  2)  test,  2 and  Exact
isher  test.  The  signiﬁcance  level  was  set  at  p  <  0.05,  odds
atio  (OR)  and  95%  conﬁdence  intervals  (CI)  for  relative  risks
ere  also  calculated  for  each  variation.
. Results
.1.  IL-4  -1098,  -590  and  -33  polymorphisms  in
ntestinal gastric  cancer
L-4  -590T  (  =  0.04;  OR  =  2.2;  95%  CI  1.1--4.4)  and  IL-4  -33T
  =  0.001;  OR  =  3.9;  95%  CI  1.7--8.9)  mutant  alleles  were
ore  frequent  among  IGC  subjects  (Table  2).  We  also  found
 higher  prevalence  of  IL-4  -590TT  (  =  0.01;  OR  =  6.7;  95%  CI
.4--32.4)  and  IL-4  -33TT  (  =  0.002;  RR  =  2.2;  95%  CI  1.7--2.8)
ow  producer  genotypes  between  IGC  patients  (Table  2).  This
endency  was  also  veriﬁed  in  IL-4  TTT  (  =  0.0002;  OR  =  5.8;
5%  CI  2.3--14.4)  mutated  haplotype  that  showed  high  inci-
ence  in  ICG  group  (Table  2).
.2.  IL-6  -174  and  nt565  polymorphisms  in
ntestinal gastric  cancer
L-6-174CG  intermediate  producer  genotype  showed  a
igher  prevalence  in  IGC  patients  (50%  vs.  12%;    =  0.0001;
R  =  7.3;  95%  CI  2.7--20.3)  (Table  2).  Additionally,  IL-6  -
74/nt565CG,  low/intermediate  producer  haplotype,  were
ounded  associated  with  IGC  patients  group  (  =  0.006;
R  =  2.2;  95%  CI  1.2--4.4)  (Table  2).
t
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.3.  IL-4  -1098,  -590  and  -33  polymorphisms  in
iffuse gastric  cancer
L-4  -33T  mutant  allele  (  =  0.003;  OR  =  3.4;  95%  CI  1.6--7.6)
as  more  frequent  between  DGC  group  (Table  3).  We
lso  found  a  higher  prevalence  of  IL-4  -1098GG  (  =  0.02;
R  =  4.4;  95%  CI  1.7--16.9)  and  IL-4  -33TT  (  =  0.0007;
R  =  2.3;  95%  CI  1.8--2.9)  low  producer  genotypes  among  DGC
et  (Table  3).  This  tendency  was  also  veriﬁed  in  IL-4  TTT
  =  0.04;  OR  =  2.3;  95%  CI  1.0--5.5)  mutated  haplotype  that
howed  high  incidence  in  ICG  group  (Table  3).
.4.  IL-6  -174  and  nt565  polymorphisms  in  diffuse
astric cancer
L6  -174C  (  =  0.0006;  OR  =  2.7;  95%  CI  1.5--4.8)  and  IL-6
174CC  (  =  0.002;  OR  =  3.8;  95%  CI  1.7--8.7),  low  pro-
ucers  variants,  showed  upper  prevalence  within  DGC
et.  On  other  hand,  IL-6  nt565G  and  nt565GG,  high
roducers  variants,  were  more  prevalent  in  DGC  sub-
ects  (  <  0.01;  OR  >  3.7;  95%  CI  1.3--18.8).  Concerning  IL-6
aplotypes  results,  low/intermediate  producer  haplotype,
74/nt565CG,  showed  a  high  incidence  in  DGC  set  (78%  vs.
1%,    <  0.0001;  OR  =  7.9;  95%  CI  4.2--14.9)  (Table  3).
. Discussion
.1.  IL-4  polymorphisms  in  gastric  cancer
L-4  plays  a  central  role  in  Th  cells  maturation  contribut-
ng  to  Th2  phenotype  differentiation.36 In  this  process,  IL-4
an  increase  anti-inﬂammatory  cytokines  production  (such
s  IL-10,  IL-13  and  itself)36 and  suppress  pro-inﬂammatory
ytokines  production  (such  as  IL-1 and  IL-8).37--39 Moreover,
ctivation  of  IL-4  pathway  can  lead  to  cell  proliferation,  cell
rowth  or  apoptosis  depending  on  the  variety  of  stimuli39
herefore,  genetic  variations  responsible  for  different  IL-4
xpression  levels,  and  consequently  for  Th  cells  differenti-
tion,  may  be  critical  in  determinate  the  pro-or  anti-tumor
mmune  response.36--43 Moreover,  IL-4  impact  in  GC  remains
nclear,  since  some  studies  associate  this  molecule  with
C  prevalence,25,39 while  other  studies  show  no  association
etween  them.38,40,42 In  this  study  we  have  evaluated  the
mpact  of  IL-4  polymorphisms  in  IGC  and  DGC  patients  and
ound  signiﬁcant  correlations  between  them.  These  results
upport  the  idea  that  IL-4  can  have  an  important  role  in  GC
evelopment,  namely  by  contributing  for  Th2  differentiation
nd  immune  modulation.
.2.  IL-4  polymorphisms  role  in  intestinal  gastric
ancer
GC  is  characterized  by  a  unique  glandular  pattern,  resem-
ling  the  gastrointestinal  tract  glands  (Fig.  1B),  and  by
 relatively  well-deﬁned/sequential  progression.35,43,44 The
volution  of  these  tumors  begins  with  gastritis  occurrence,ritis),  followed  by  intestinal  metaplasia,  dysplasia  and
arcinoma.35,43 IGC  is  often  described  as  a  result  of  per-
istent  chronic  inﬂammation,  Hp-dependent.3,35,44 In  this
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Table  2  IL-4  and  IL-6  allele/genotype  frequencies  among  CG  and  IGC  groups.
Polymorphism  CG  IGC    OR  (95%  CI)  RR  (95%  CI)
n (%)  n  (%)
IL-4
(-1098)
Alelles
T  75(75)  75(75)  n.s  1.0*  . . .
G 25(25)  25(25)  n.s  1.0*  . . .
Genotype
TT 28(56)  28(56)  n.s  1.0*  . . .
TG 19(38)  19(38)  n.s  1.0*  . . .
GG 3(6)  3(6)  n.s  1.0*  . . .
IL-4
(-590)
Allele
C 85(85) 72(72) 0.04  0.5  (0.2--1.0)  0.7  (0.5--1.0)
T 15(15) 28(28) 0.04  2.2  (1.1--4.4) 1.4  (1.1--1.9)
Genotype
CC 28(56)  30(60)  n.s  . . . . . .
CT 20(40)  9(18)  0.02  0.3  (0.1--0.8)  0.5  (0.3--1.0)
TT 2(4)  11(22)  0.01  6.7  (1.4--32.4)  1.9  (1.3--2.6)
IL-4
(-33)
Allele
C 91(91)  72(72)  0.001  0.3  (0.1--0.6)  0.6  (0.5--0.8)
T 9(9)  28(28)  0.001  3.9  (1.7--8.9)  1.7  (1.3--2.2)
Genotype
CC 41(82)  30(60)  0.04  0.4  (0.1--0.9)  0.6  (0.4--0.9)
CT 9(18)  11(22)  n.s  . . . . . .
TT 0(0)  9(18)  0.002  . . . 2.2  (1.7--2.8)
IL-4
(-1098/-590/-33)
Haplotype
TCC 60(60)  47(47)  n.s  . . . . . .
TTT 9(9)  28(28)  0.0002  5.8  (2.3--14.4)  2.2  (1.5--3.2)
GCC 25(25)  25(25)  n.s  --  --
TCT 0(0)  0(0)  n.s  --  --
TTC 6(5)  0(0)  0.01  . . . . . .
GTT 0(0)  0(0)  n.s  . . . . . .
IL-6
(-174)
Allele
C 44(44)  42(42)  n.s  . . . . . .
G 56(56)  58(58)  n.s  . . . . . .
Genotype
CC 19(38)  17(34)  n.s  . . . . . .
CG 6(12)  25(50)  0.0001  7.3  (2.7--20.3)  2.2  (1.6--3.2)
GG 25(50)  8(16)  0.0006  0.2  (0.1--0.5)  0.4(0.2--0.7)
IL-6
(nt565)
Allele
G 78(78)  81(81)  n.s  . . . . . .
A 22(22)  19(19)  n.s  . . . . . .
Genotype
GG 38(76)  39(78)  n.s  . . . . . .
GA 3(6)  3(6)  n.s  . . . . . .
AA 9(18)  8(16)  n.s  . . . . . .
IL-6
(-174/nt565)
Haplotype
GG 47(47)  31(31)  0.02  0.5  (0.3--0.9)  0.7  (0.5--1.0)
CA 13(13)  8(8)  n.s  . . . . . .
CG 31(31)  50(50)  0.006  2.2  (1.2--4.0)  1.5  (1.1--1.9)
GA 9(9)  11(11)  n.s  . . . . . .
CG-Chronic Gastritis; IGC-Intestinal Gastric Cancer; n-Absolute Number; -Probability; n.s-Non-Statiscally Signiﬁcant; OR-Odds Ratio;
RR-Relative Risk; CI-conﬁdence Interval; *- Reference.
148  A.M.  Sampaio  et  al.
Table  3  IL-4  and  IL-6  allele/genotype  frequencies  among  CG  and  DGC  groups.
Polymorphism  CG  DGC    OR  (95%  CI)  RR  (95%  CI)
n (%)  n  (%)
IL-4
(-1098)
Allele
T  75(75)  64(64)  n.s  .  .  . .  . .
G 25(25)  36(36)  n.s  .  .  . .  . .
Genotype
TT 28(56)  25(50)  n.s  .  .  . .  . .
TG 19(38)  14(28)  n.s  .  .  . .  . .
GG 3(6)  11(22)  0.02  4.4  (1.1--16.9)  1.7  (1.2--2.4)
IL-4
(-590)
Allele
C 85(85) 77(77) n.s  .  .  . .  . .
T 15(15) 22(22) n.s  .  .  . .  . .
Genotype
CC 28(56)  39(78)  0.02  2.8  (1.1--6.7)  1.7  (1.0--2.9)
CT 20(40)  11(22)  n.s  .  .  . .  . .
TT 2(4)  0(0)  n.s  .  .  . .  . .
IL-4
(-33)
Allele
C 91(91)  75(75)  0.003  0.3  (0.1--0.7)  0.6  (0.5--0.8)
T 9(9)  25(25)  0.003  3.4  (1.4--7.6)  1.6  (1.2--2.1)
Genotype
CC 41(82)  37(74)  n.s  .  .  . .  . .
CT 9(18)  2(4)  0.03  0.2  (0.04--0.9)  0.3  (0.1--1.2)
TT 0(0)  11(22)  0.0007  .  .  . 2.3  (1.8--2.9)
IL-4
(-1098/-590/-33)
Haplotype
TCC 60(60)  42(42)  0.01  0.5  (0.3--0.8)  0.7  (0.5--0.9)
TTT 9(9)  19(19)  0.04  2.3  (1.0--5.5)  1.4  (1.0--1.9)
GCC 25(25)  33(33)  n.s  .  .  . .  . .
TCT 0(0)  2(2)  n.s  .  .  . .  . .
TTC 6(6)  0(0)  0.02  .  .  . .  . .
GTT 0(0)  4(4)  0.05  .  .  . 2.0  (1.8--2.4)
IL-6
(-174)
Allele
C 44(44)  68(68)  0.0006  2.7  (1.5--4.8)  1.7  (1.2--2.9)
G 56(56)  32(32)  0.0006  0.4  (0.2--0.7)  0.6  (0.4--0.8)
Genotype
CC 19(38)  35(70)  0.002  3.8  (1.7--8.7)  2.0  (1.3--3.1)
CG 6(12)  11(22)  n.s  .  .  . .  . .
GG 25(50)  4(8)  <0.0001  0.1  (0.02--0.3)  0.2  (0.1--0.5)
IL-6
(nt565)
Allele
G 78(78)  93(93)  0.003  3.7  (1.5--9.2)  2.3  (1.2--4.4)
A 22(22)  7(7)  0.003  0.3  (0.1--0.7)  0.4  (0.2--0.9)
Genotype
GG 38(76)  47(94)  0.01  4.9  (1.3--18.8)  2.7  (1.0--7.7)
GA 3(6)  0(0)  n.s  .  .  . .  . .
AA 9(18)  3(6)  n.s  .  .  . .  . .
IL-6
(-174/nt565)
Haplotype
GG 47(47)  15(15)  <0.0001  0.2  (0.1--0.4)  0.4  (0.3--0.6)
CA 13(13)  7(7)  n.s  .  .  . .  . .
CG 31(31)  78(78)  <0.0001  7.9  (4.2--14.9)  3.0  (2.0--4.3)
GA 9(9)  0(0)  0.003  .  .  . .  . .
CG-Chronic Gastritis; DGC-Diffuse Gastric Cancer; n-Absolute Number; -Probability; n.s-Non-Statistically Signiﬁcant; OR-Odds Ratio;
RR-Relative Risk; CI-conﬁdence Interval; *- Reference.
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sense,  IL-4  polymorphisms  can  inﬂuence  this  cancer  type
susceptibility  and  risk.
In  this  work  we  have  found  that  the  presence  of  IL-4
mutant  alleles  (IL-4  -590T  and  IL-4  -33T)  are  correlated  with
IGC  occurrence.  Contrasting,  the  high  production  variants
(IL-4  -590C,  IL-4  -33C  and  IL-4  -33CC)  are  correlated  with  CG
prevalence.  As  IL-4  plays  a  central  role  in  Th  cells  maturation
to  Th2  phenotype,  decreases  in  this  molecule  production
results  in  Th2  response  reduction.24,41,42 This  molecule  can
act  as  IFN,  IL-1  and  TNF  inhibitor,  decreasing  the  cells  pro-
inﬂammatory  responses.  It  also  been  reported  than  IL-4  may
contribute  to  cell-mediated  immunity.38--42 Those  processes
can  be  responsible  for  increased  gastric  mucosa  deregulated
proliferation,  triggered  by  pro-inﬂammatory  cytokines  (such
as  IL-1 and  IL-8).24,38--42 Cellular  deregulation/proliferation
can  be  the  main  cause  of  tumor  development  in  IGC  patients.
These  ﬁndings  are  in  agreement  with  those  previously
described  by  Wu  and  collaborators,39 in  2003,  which  refer
the  low  IL-4  production  (IL-4  -590TT  genotype)  as  respon-
sible  for  the  development  of  gastric  carcinoma  and  high
production  (IL-4  -590CC  genotype)  as  responsible  for  the
development  of  peptic  ulcer.39
4.3.  IL-4  polymorphisms  role  in  diffuse  gastric
cancer
DGC  is  characterized  by  individualized  neoplastic  cells,  vari-
able  stroma  and  sometimes  signet  ring  cells  (Fig.  1C).45--48
This  kind  of  cancer  develops  subsequently  to  chronic  infec-
tion,  without  going  through  atrophic  gastritis  and  intestinal
metaplasia  steps.48 DGC  has  a  great  predisposition  for  intra
and  transmural  growth,  is  highly  metastatic  and  has  poor
clinical  outcome.45--48 As  in  IGC,  IL-4  polymorphisms  can
inﬂuence  DGC  susceptibility.
In  this  study,  we  have  seen  that  IL-4  cytokine  low  pro-
duction  variants  particularly,  IL-4  -33T  allele,  IL-4  -1098GG
and  IL-4  -33TTgenotypes,  IL-4  -1098/-590/-33  TTT  and  IL-
4  -1098/-590/-33  GTT  haplotypes,  are  correlated  with  DGC
prevalence.  Simultaneously,  IL-4  -33C  allele,  IL-4-590CC  and
IL-4  -33CT  genotypes  and  IL-4  -1098/-590/-33  TCC  haplo-
type  (associated  with  high  IL-4  production)  are  correlated
with  chronic  gastritis  incidence.  Resuming,  IL-4  high  produc-
tion  appears  to  have  a  protective  effect  in  DGC,  while  low
production  of  this  cytokine  seams  to  increase  the  DGC  risk.
Consequently,  decreased  IL-4  production  leads  to  gastric
mucosa  tissue  breakdown  increase  and  tumor  development,
triggered  by  Th2  pathway  absence  (downregulating  IL-10,
IL-13).24,42--44,49 Although  there  are  no  studies  on  IL-4  poly-
morphisms  that  compare  individuals  with  CG  and  DGC,  these
ﬁndings  are  conﬂicting  with  previous  studies  involving  poly-
morphisms  responsible  for  IL-4  high  production  on  gastric
cells,  maybe  duo  to  sample  and/or  population  features.25,49
However,  the  results  obtained  in  this  work  are  consistent
with  those  obtained  for  IGC.
4.4.  IL-6  polymorphisms  in  gastric  cancerIL-6  is  a  cytokine  with  dual  role  in  the  immune  system,  whose
role  in  carcinogenesis  is  not  yet  fully  understood.26--32 This
molecule  can  promote  tumor  growth  by  inhibiting  cancer
cells  apoptosis  and  inducing  tumor  angiogenesis.30--32 IL-6  is
c
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lso  very  important  at  systemic  level,  stimulating  ﬁbroblasts
nd  epithelial  cells  to  secrete  IL1-Ra  and  promoting  down-
egulation  of  anti-inﬂammatory  activity.30,31,50 IL-6  are  also
nvolved  NF-B  down-modulation  activities  by  E-cadherin  in
C.19 E-cadherin  can  rise  IL-6  and  TNF  expression  leading  to
educed  cell  apoptosis  and  increased  cell  survival.19 These
olecules  can  also  mediate  inﬂammation  associated  cancer
evelopment  mechanisms,  including  Hp  infection.  For  those
easons,  high  IL-6  levels  are  associated  with  worse  prognosis
n  advanced  GC  cases.27,51,52 Polymorphisms  in  IL-6  promoter
egion,  particularly  at  -174  position,  have  great  study  inter-
st  because  it  has  been  reported  its  association  with  cancer
revalence  and/or  prognosis.26,30,31,50,52--55 In  spite  this  asso-
iation,  IL6  role  in  GC  development/predisposition  remains
oubtful  with  conﬂicting  results.54,55 In  this  work,  IL6  -
74G>C  and  nt565  G>C  polymorphisms  showed  an  important
ssociation  among  IGC,  DGC  and  CG  sets.  These  ﬁndings
upports  the  idea  that  IL-6  contributes  to  GC  carcinogenic
evelopment  process,  mostly  by  regulating  pro-  and/or  anti-
nﬂammatory  activities  in  Hp-infected  tissue.
.5.  IL-6  polymorphisms
.5.1.  Role  in  intestinal  gastric  cancer
ince  IGC  is  normally  described  as  a  result  of  continuous
hronic  inﬂammation,35,43--45 Hp-dependent,  and  IL-6  regu-
ate  inﬂammatory  responses,26--32 it  can  be  expected  that
L-6  polymorphisms  can  inﬂuence  ICG  risk.  In  this  study,
he  incidence  of  IL-6  low  producers’  genotype  (IL-6  -174CG)
nd  haplotype  (IL-6  -174/nt565  CG)  were  correlated  with
GC  set.  On  the  other  hand,  IL-6  high  producers’  genotype
IL-6  -174GG)  and  haplotype  (IL-6  -174/nt565GG)  showed  a
igniﬁcant  association  with  CG  prevalence.  Our  results  sug-
est  that  IL-6  over-expression  have  a  protective  role  in  IGC
ubjects,  while  its  down-regulation  appears  to  increase  IGC
redisposal.  Our  data  are  only  corroborated  by  Kamangar  et
l55 work,  where  IL-6  low  producer  genotype  (IL-6  -174CG)
howed  a  higher  risk  for  GC  predisposal.55 Even  though,
here  might  be  several  possible  mechanisms  underlying  this
esults,  including  sample  outcomes,  since,  GC  development
ccurs  from  both  environmental  and  genetic  factors  interac-
ions.  Nevertheless,  it  is  well  known  that  the  decreased  on
L-6  production  results  in  macrophages  anti-tumor  activity
nd  tumor  cells  lyses  full  drop.56 On  the  other  hand,  since  IL-
 is  Th3  cytokine,  down-regulation  of  this  molecule  may  also
rigger  an  increase  of  Th1  response  (stimulating  TNF,  IL-1
nd  IL-8  expression)  that  leads  to  uncontrolled  inﬂammation
nd,  consequently,  to  gastric  carcinogenesis.26--32,50,52--56
.6.  IL-6  polymorphisms  role  in  diffuse  gastric
ancer
nce  DGC  is  deﬁned  as  a  result  of  chronic
nﬂammation,36,46--48 and  IL-6  is  involved  in  E-cadherin19 and
nﬂammatory  pathways,52--56 we  can  estimated  an  important
ole  of  IL-6  polymorphisms  in  DGC  risk.  This  hypothesis  was
orroborated  with  our  results,  since  we  have  found  a  high
orrelation  between  DGC  subjects  and  IL-6  low  production
ariants  (IL-6  -174C  allele,  IL-6  -174  CC  genotype  and  IL-6
174/nt565CG  haplotype).  Additionally,  in  this  work,  IL-6
igh  production  polymorphisms  (IL-6  -174G  allele,  IL-6  -174
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150  
G  genotype  and  IL-6  -174/nt565GG  and  GA  haplotypes)
howed  a  signiﬁcant  association  with  CG  occurrence.  As
n  IGC,  the  IL-6  over-expression  was  correlated  with  DGC
rotection,  while  its  low  production  seams  to  increase
he  risk  of  DGC  occurrence.50 IL-6  involvement  in  DGC  can
lso  be  explained  by  E-cadherin  pathway,  since  E-cadherin
an  inﬂuence  IL-6  and  TNF  expression  modulating  cell
poptosis,  cell  survival,  cell  migration,  and  inﬂammation
ssociated  gastric  cancer  development.19 In  this  way,  as
n  IGD,  a  decrease  of  IL-6  production  is  associated  with
n  increase  of  Th1  (upregulating  TNF,  IL-1  and  IL-8)  and
 decrease  of  Th2  activities  (downregulating  IL-10,  IL-13
nd  IL-4)50,52--56 that  could  lead  to  a  deregulation  in  chronic
nﬂammation  process.17,18 Alternatively  to  IL-6  dual  Th
ole  in  inﬂammation  process,  these  results  could  also
e  explained  by  its  activity  in  macrophages  anti-tumor
esponses  regulation.26--32,50,52--56 These  ﬁndings  are  con-
istent  with  some  results  previously  described  for  diffuse
ype32 and  with  those  obtained  for  the  intestinal  type.55
.7.  Study  limitations
here  might  be  several  possible  mechanisms  underlying
ll  association  studies,  such  as,  the  results  from  interplay
f  both  environmental  and  genetic  factors,  which  can  be
esponsible  for  analysis  default.  The  sample  size  of  the
resent  study  (50  DCG,  50  IGC  and  50  controls)  might  not
e  large  enough  to  detect  small  effect  of  low  penetrance
utations.  The  combine  effect  of  multiple  genes/mutations
an  provide  more  reliable  information  for  genetic  contri-
ution  to  risk  of  GC.  We  cannot  completely  exclude  the
ffects  of  the  other  conditions  (i.e.  age,  weight,  gender,
iet  type,  etc.. .  .) and  residual  confounding  attributable  to
he  measurement  error  (namely,  unicentric  characters,  lack
f  assess  of  Hp  status  in  GC  subjects,  etc.. .  .). It  is  essential
 large  approaching  study  with  large  sample  size  to  conﬁrm
ur  outcomes.  Still,  the  present  study  provides  preliminary
vidence  that  IL-6  and  IL-4  expression  variants,  may  con-
ribute  to  the  risk  of  GC  in  Portuguese  Population,  and  may
e  useful  tools  in  the  study  of  this  multifactorial  disorder.
evertheless,  large  approaching  studies  with  large  sample
ize  are  essential  to  conﬁrm  our  outcomes.
. Conclusions
ytokines  studied  in  this  work  seem  to  play  an  important
ole  in  both  DGC  and  IGC  development  risk.  It  was  clear  that
L-4  and  IL-6  polymorphisms  could  make  individuals  more
nd/or  less  susceptible  to  GC,  independently  of  its  histolog-
cal  type.  Although  some  of  these  data  have  not  yet  been
escribed,  these  ﬁndings  raise  important  questions  about
ytokines  activity  in  gastric  cancer  genesis.  IL-4  and  IL-6
xpression  variants  can  manipulate  some  of  tumor  develop-
ent  mechanisms.  Those  molecules  high  production  variants
ppear  to  have  a  protective  role  in  both  IGC  and  DGC,
hile  the  low  production  modiﬁcations  seem  to  increase  GC
usceptibility.  Still,  his  kind  of  study  is  quite  important  in
ountries  like  Portugal,  with  high  levels  of  gastric  disease,
ince  we  can  improve  the  GC  individual  risk  determination
sing  cytokine  polymorphisms  as  a  tool.  Moreover,  this  study
rovides  preliminary  evidence  that  cytokine  polymorphism
1A.M.  Sampaio  et  al.
namely,  IL-4  and  IL-6)  determination  could  be  useful  to
ollow  up  patients  and  relatives  in  our  population.  Never-
heless,  large  approaching  studies  with  large  sample  size
re  essential  to  conﬁrm  our  outcomes.
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